Answers are grounded in this paper and cite their sources.
It was hypothesized that a high dose of estrogen in conjunction with a long-acting PGF2 alpha analog would synchronize parturition within a narrow time frame and reduce the incidence of retained placenta. On d 276 of gestation, 14 animals (9 cows and 5 heifers) per group received a placebo (group A), 1 mg of fenprostalene (group B), 50 mg of estradiol-17 beta benzoate (group C), or both (group D). Treatment with estradiol-17 beta benzoate increased serum concentrations of estradiol-17 beta from 228 pg/ml at treatment to 642 and 683 pg/ml at 24 h posttreatment for groups C and D, respectively. Concentration of estradiol-17 beta in group A increased gradually to 526 pg/ml at 24 h prepartum. Progesterone concentrations were reduced by fenprostalene but not by estradiol-17 beta benzoate. Estradiol-17 beta benzoate did not reduce incidence of retained placenta in animals treated with fenprostalene (group B vs. group D) but tended to reduce incidence in uninduced animals (group A vs. group C). Thus, short-term elevation of estradiol-17 beta to normal prepartum concentrations did not regress the corpus luteum, induce parturition, or reduce incidence of retained placenta. However, elevation of estradiol-17 beta for longer periods might enhance placental separation. Conversely, fenprostalene induced calving approximately 2 d after treatment. In this study, 90% of animals treated with fenprostalene calved within a 20-h period, but with a high incidence of retained placenta.
No takes yet. Share an insight, caveat, or question.
Rasmussen et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: